Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
oratinib
- Development stage
- Unknown
- Lead developer
- Taiho Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Oratinib (SM-1) is an orally bioavailable, multi-target tyrosine kinase inhibitor (TKI) developed by Shenzhen Zhenxing Pharmaceutical Technology. It is designed to inhibit several key pathways involved in tumor growth and angiogenesis, specifically targeting the vascular endothelial growth factor receptors (VEGFR1, VEGFR2, and VEGFR3), fibroblast growth factor receptors (FGFR1, FGFR2, and FGFR3), and platelet-derived growth factor receptors (PDGFRα and PDGFRβ). Formulated as oratinib fumarate in enteric-coated capsules to optimize its pharmacokinetic profile, the drug is currently being evaluated in Phase II clinical trials for the treatment of advanced small intestinal adenocarcinoma (SIA) in patients who have failed prior standard systemic therapies. Its multi-kinase inhibition profile aims to provide a therapeutic option for rare and aggressive gastrointestinal malignancies by blocking both tumor cell proliferation and the formation of new blood vessels.
- Other names
- oratinib fumarateAolatinib
02
Targets
PDGFRA (Platelet-derived growth factor receptor alpha)PDGFRB (Platelet-derived growth factor receptor beta)FGFR3 (Fibroblast growth factor receptor 3)VEGFR2 (Vascular endothelial growth factor receptor 2)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR3 (Vascular endothelial growth factor receptor 3)FGFR2 (Keratinocyte growth factor receptor)FGFR1 (Fibroblast growth factor receptor 1)
Beyond the preview
Go deeper on oratinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on oratinib.